OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in
Long Island, New York with facilities in Colorado, New Jersey and the United ...
Agensys, Inc., a subsidiary of Astellas Pharma Inc. is developing a pipeline of
therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor
About OSI Pharmaceuticals OSI Pharmaceuticals, acquired by Astellas Pharma
Inc. in 2010, is a leading biotechnology company focused on the discovery and ...
Genentech USA, Inc. and Astellas Pharma US, Inc. hereby authorize you to copy
documents or pages published by Genentech USA, Inc. and Astellas Pharma ...
OSI Pharmaceuticals Announces Acceptance of a Tarceva(R) Supplemental New
Drug. Application in Pancreatic Cancer for Review by the U.S. Food and Drug ...
As of May, 2013, OSI Pharmaceuticals Inc. went out of business. OSI
Pharmaceuticals Inc. offers oncology drug discovery and translational research
May 13, 2013 ... OSI Pharmaceuticals, once the bright hope in Long Island's struggle to build a
bioscience industry, is shuttering its remaining facility in the ...
Jun 16, 2004 ... OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing
Agreements for Tarceva. Melville, N.Y. and South San ...
Jan 8, 2001 ... OSI Pharmaceuticals, Genentech and Roche Team up to Deveolp and
Commercialize OSI-774, OSI's Leading Cancer Drug to Develop and ...
OSI's detailed financings; Comprehensive pipeline breakdown, including
molecular targets & partnerships. 17 years of in-depth BioPharma industry